User login
Key clinical point: Exogenous digestive enzyme replacement was associated with increased weight gain and head circumference growth in very low birth weight preterm infants with growth failure and signs and symptoms of exocrine pancreatic insufficiency (EPI).
Major finding: Average daily weight gain increased from 14.4 g/kg/day to 17.4 g/kg/day (P = .001) and head circumference growth rate increased from 0.74 cm/week to 0.95 cm/week (P = .028) during 2 weeks following administration of digestive enzyme replacement.
Study details: This was a retrospective study of 132 preterm infants with gestational age below 2 weeks and birth weight below 1250 g who survived for more than 14 days. Growth restriction despite intensified nutrition and poor exocrine pancreatic function was observed in 66 and 38 infants, respectively, of which 33 infants recieved exogenous digestive enzyme replacement.
Disclosures: No specific funding source was identified. Open Access was funded by ProjektDEAL. The authors declared no conflicts of interest.
Source: Münch A et al. Eur J Pediatr. 2021 Apr 10. doi: 10.1007/s00431-021-04069-0.
Key clinical point: Exogenous digestive enzyme replacement was associated with increased weight gain and head circumference growth in very low birth weight preterm infants with growth failure and signs and symptoms of exocrine pancreatic insufficiency (EPI).
Major finding: Average daily weight gain increased from 14.4 g/kg/day to 17.4 g/kg/day (P = .001) and head circumference growth rate increased from 0.74 cm/week to 0.95 cm/week (P = .028) during 2 weeks following administration of digestive enzyme replacement.
Study details: This was a retrospective study of 132 preterm infants with gestational age below 2 weeks and birth weight below 1250 g who survived for more than 14 days. Growth restriction despite intensified nutrition and poor exocrine pancreatic function was observed in 66 and 38 infants, respectively, of which 33 infants recieved exogenous digestive enzyme replacement.
Disclosures: No specific funding source was identified. Open Access was funded by ProjektDEAL. The authors declared no conflicts of interest.
Source: Münch A et al. Eur J Pediatr. 2021 Apr 10. doi: 10.1007/s00431-021-04069-0.
Key clinical point: Exogenous digestive enzyme replacement was associated with increased weight gain and head circumference growth in very low birth weight preterm infants with growth failure and signs and symptoms of exocrine pancreatic insufficiency (EPI).
Major finding: Average daily weight gain increased from 14.4 g/kg/day to 17.4 g/kg/day (P = .001) and head circumference growth rate increased from 0.74 cm/week to 0.95 cm/week (P = .028) during 2 weeks following administration of digestive enzyme replacement.
Study details: This was a retrospective study of 132 preterm infants with gestational age below 2 weeks and birth weight below 1250 g who survived for more than 14 days. Growth restriction despite intensified nutrition and poor exocrine pancreatic function was observed in 66 and 38 infants, respectively, of which 33 infants recieved exogenous digestive enzyme replacement.
Disclosures: No specific funding source was identified. Open Access was funded by ProjektDEAL. The authors declared no conflicts of interest.
Source: Münch A et al. Eur J Pediatr. 2021 Apr 10. doi: 10.1007/s00431-021-04069-0.